Are we proof that a new drug to stop diseases like arthritis and type 1 diabetes really DOES work?

Mahn Singh is the first British child to be part of a trial for a new drug, teplizumab, which blocks the immune system malfunction that destroys insulin-producing cells and causes type 1 diabetes.

Related Keywords

Northwick ,Cheshire West And Chester ,United Kingdom ,North Yorkshire ,London ,City Of ,Harrogate ,Dealing ,Britain ,Britons ,British ,Rachel Besser ,Paul Howard ,Wendy Holden ,Kevan Herold ,Harj Mahn ,Mikayla Olsen ,Hilary Nathan ,Colin Dayan ,Mahn Singh ,Daisy Abbs ,Joe Brunwin ,Drug Administration ,Yale School Of Medicine ,Department Of Health ,National Screening Committee ,National Diabetes Audit ,Oxford University ,Good Health ,Innovation Advisory Committee ,Cardiff University ,University Hospital Of Wales ,Regulatory Agency ,Diabetes Research Foundation ,Ms Society ,Newborn Research ,West London ,Recent Onset Type ,Trial Evaluating Efficacy ,Northwick Park Hospital ,University Hospital ,Sheffield Children ,Professor Colin Dayan ,New England Journal ,Yale School ,Juvenile Diabetes Research Foundation ,Diabetes Audit ,National Screening ,Innovation Passport ,Social Care ,Arthritis United ,Lupus United Kingdom ,Dailymail ,Health ,Diabetes ,